Stockscreener 앱 받기
5.75
0.61%
-0.03
전일 마감가:
$5.78
열려 있는:
$5.85
하루 거래량:
102.02K
Relative Volume:
11.29
시가총액:
$36.42M
수익:
-
순이익/손실:
$-14.72M
주가수익비율:
-
EPS:
-
순현금흐름:
$-7.41M
1주 성능:
+1.23%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.70
$5.85
1주일 범위
$5.35
$5.85
52주 변동 폭
$5.35
$5.85
Alpha Cognition Inc Stock (ACOG) Company Profile
ACOG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ACOG | 5.7538 | 36.42M | 0 | -14.72M | -7.41M | 0.00 |
| VRTX | 449.73 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.37 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.51 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.06 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alpha Cognition Inc 주식(ACOG)의 최신 뉴스
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - Business Wire
Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com
Alpha cognition director John Havens buys $24,995 in common shares - Investing.com India
Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alpha Cognition Inc (ACOGF) Quarterly 10-Q Report - Quartzy
Canada market stock losers: Tidewater Renewables Ltd. looses 12.43% while Rektron Group Inc dips by 10.33% during mid day trading - Business Upturn
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing - Business Wire
Canada Market Top Losers: AYR Wellness down 47.30%, Trulieve Cannabis falls 40%, - Business Upturn
Alpha Cognition Inc. announced that it has received $4.545 million in funding - Marketscreener.com
Alpha Cognition Plans Nasdaq Listing and $25M Offering - TipRanks
Xavier Creative House Hires Jami Rogers as Vice President of Sales & Marketing - citybiz
Alpha Cognition Announces Appointment of VP Finance and Accounting - Business Wire
Alpha Cognition Inc (ACOGF) QuotePress Release - The Globe and Mail
Alpha Cognition Announces Executive Shake-up & Drug Approval - TipRanks
Alpha Cognition Announces Change of Officer - Business Wire
Spartan Capital Securities Serves as Selling Group Member - GlobeNewswire
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing - BioSpace
Alpha Cognition sets annual meeting for September 27 - Investing.com
July FDA approvals target Alzheimer's, myeloma and wet AMD - BioWorld Online
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease - Yahoo Finance
Alpha Cognition Inc. Adjusts Funding Strategy Amid Market Challenges - TipRanks
FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatment - News-Medical.Net
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease - Seeking Alpha
FDA favors Zunveyl, Alzheimer's therapy showing better tolerability - Alzheimer's News Today
FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's disease | 2024-07-29 | Investing News - Stockhouse Publishing
Breakeven On The Horizon For Alpha Cognition Inc. (CSE:ACOG) - Simply Wall St
Alpha Cognition upgraded at Raymond James - Cantech Letter
Early Inflammation Linked to Midlife Cognitive Decline - Neuroscience News
What’s Coming Down the Pike: Drug Approvals in the Second Half of ’24 - Managed Healthcare Executive
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update - Business Wire
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer’s (NASDAQ:CGTX) - Seeking Alpha
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - Yahoo Finance
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now - GlobeNewswire
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease - Yahoo Finance
Alpha Cognition Provides Business Update - Business Wire
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering - Yahoo Finance
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease - Business Wire
BioNTX iC3 Summit to Fuel North Texas Life Science Ecosystem, Honor 8 Rising Stars - dallasinnovates.com
Alpha Cognition gets rating downgrade from Raymond James - Cantech Letter
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire
Data: ALPHA-1062 a Bioequivalent to Approved Therapy Razadyne - Alzheimer's News Today
Progranulin Gene Therapy Shows Promise in Preclinical Studies - ALS News Today
Alpha Cognition could have a best-in-class Alzheimer’s drug, iA Capital says - Cantech Letter
Pharmaceutical Entrepreneur Fred Sancilio Speaks on His Vast Industry Experience - Thrive Global
Alpha Cognition Inc (ACOG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alpha Cognition Inc 주식 (ACOG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
1.80%
0.42%
자본화:
|
볼륨(24시간):